SAN CARLOS, Calif. — Alkahest Inc. (“Alkahest”), a clinical-stage biotechnology company focused on developing innovative therapies to treat age-related diseases, today announced upcoming presentations at the Society for Neuroscience 47th Annual Meeting, taking place November 11-15, 2017 in Washington, DC. The Alkahest team will present preclinical data further elucidating the role of the plasma proteome in age-related cognitive dysfunction and neurodegeneration.
“These findings add to the growing body of research supporting our hypothesis that factors in the plasma proteome play an important role in age-related disease, particularly in dementia and neurodegenerative disorders,” said Karoly Nikolich, Ph.D., Chief Executive Officer of Alkahest. “As the world’s population grows older, the burden of age-related diseases will quickly become one of the greatest medical challenges of our generation. Our suite of innovative therapeutics targeting the plasma proteome are currently in clinical development, and are well-positioned to address this critical need.”
These preclinical data demonstrate that factors in the plasma proteome may have behavioral and histological effects in animals. Investigators explored young human plasma as a positive regulator for brain health, as well as aged human plasma that may be a source of negative regulators of brain health. Together, this collection of preclinical data improves the understanding of the underlying biological mechanisms of age-related cognitive dysfunction and neurodegenerative processes, and provides insights on how to best develop therapeutics building on the benefits of plasma.
Persistence of cognitive deficits in the absence of systemic inflammation following acute LPS administration in immune-competent and immunodeficient mice
Presenter: Sanket Rege
Date: Monday, November 13th
Time: 9:00 ET
Effects of young and aged human plasma on aged murine hippocampal neurogenesis and survival # 8760
Presenter: Marian Castro
Date: Wednesday, November 15th
Time: 1:00 ET
Characterization of kainic acid-induced excitotoxic injury in immune deficient NSG mice #9446
Presenter: Angela Liu
Date: Wednesday, November 15th
Time: 1:00 ET
Aged human plasma administration negatively influences neurogenesis and cognition in young immunodeficient mice #9295
Presenter: Christine Tun
Date: Wednesday, November 15th
Time: 1:00 ET
Longevity of beneficial effects with young human plasma treatment #9830
Presenter: Raniel Alcantara-Lee
Date: Wednesday, November 15th
Time: 1:00 ET
About Alkahest
Alkahest is a privately-held company based in San Carlos, CA developing treatments for age-related diseases, with an emphasis on cognitive dysfunction and neurodegeneration — key medical challenges of our generation. The Company’s breakthrough research has demonstrated that healthy blood plasma is able to reverse brain deficits in normal aging and disease models in animals. Alkahest is developing a pipeline of first-in-class products, including novel plasma-based products in collaboration with Grifols, a global healthcare company and leading producer of plasma therapies. Alkahest’s lead clinical candidate is a proprietary plasma-derived product that has been demonstrated to enhance cognition in preclinical studies and is well-tolerated in humans. It is currently in clinical development for the treatment of Alzheimer’s disease and will be produced by Grifols. For further information, see www.alkahest.com.
Contact Information
Joe McCracken
Vice President Business Development
Alkahest, Inc.
650-245-2973
jmccracken@alkahest.com
Matthew Shinseki
Stern Investor Relations, Inc.
212-362-1200
matthew@sternir.com